Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC
Lauren A. Byers, MD
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
Luis Paz-Ares, MD, PhD
Transformative Insights: Latest Evidence for B7-H3 ADCs From WCLC and ESMO 2025
Advanced Therapeutic Strategies and Resistance Mechanisms in CLL
Shankara Paneesha, MD FRCP FRCPath
MET and Other Emerging Targets in Metastatic NSCLC
Stephen Liu, MD
Joshua K. Sabari, MD
Susan Scott, MD
Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC
Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma
John M. Kirkwood, MD
Paolo A. Ascierto, MD
Hussein Tawbi, MD, PhD
Sapna Patel, MD
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
Novel Therapies in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
The Current Therapeutic Landscape in Unresectable Stage III NSCLC
Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment
Scott Kopetz, MD, PhD
Cathy Eng, MD, FACP
Chemotherapy Strategies in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Eileen O’Reilly, MD
Efrat Dotan, MD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.